Alzheimer's disease

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

Ozempic’s latest health benefit may be cutting dementia risk

Another week, and another study has emerged pointing to a way that GLP-1 receptor agonists may benefit human health.

News

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch it at a cost it claims could deliver savings compared to a rival therapy fro

News

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Diagnostics giant Roche is putting its weight behind a biomarker for Alzheimer’s disease developed by ALZpath.

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

Novo leads $100m financing for Alzheimer's player Asceneuron

Ozempic’s latest health benefit may be cutting dementia risk

Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage

ALZpath licenses Alzheimer’s diagnosis tech to Roche

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Eisai, Biogen start delayed subcutaneous Leqembi filing

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Alzheimer's disease

Editor's Picks